Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Based on the analysis of cases provided by the MAHs, while some cases are poorly documented and confounding factors reported in other cases, suggestive elements regarding chronology and outcome were retrieved. Among the 50 cases with a reported time to onset, 29 (58%) occurred within a week, and 18 (36%) occurred the same day. Among the 33 cases with a reported outcome, 26 (79%) recovered following withdrawal of the treatment, and 7 (21%) cases were reported with a positive rechallenge. A plausible pharmacological mechanism for this ADR could be explained considering that dorzolamide belongs to the therapeutic class of carbonic anhydrase inhibitor, which has diuretic properties, and promotes the excretion of potassium. Hypokalemia (including mild) may cause change in blood pressure and abnormal heart rhythm. Therefore, based on these data, the PRAC proposes to update the product information of dorzolamide containing medicinal products to add palpitations with a frequency not known.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for dorzolamide the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing dorzolamide is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing dorzolamide are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8

The following adverse reaction should be added under the SOC Cardiac disorders with the frequency 'not known':

Palpitations

Package Leaflet

- Section 4

Not known (frequency cannot be estimated from the available data):

-**forceful heartbeat that may be rapid or irregular (palpitations)**

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	October 2019 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	01 December 2019
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	30 January 2020